Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth

Area of Science:

• Bone biology and cancer research
• Cell signaling pathways
• Hematologic malignancies

Background:

• Canonical Wnt signaling is crucial for bone homeostasis.
• Multiple myeloma (MM) cells secrete Wnt inhibitors, promoting bone resorption and disease progression.

Purpose of the Study:

• To investigate the effects of Wnt3a on multiple myeloma (MM) bone disease and MM cell growth.
• To evaluate Wnt3a as a potential therapeutic agent for MM.

Main Methods:

• In vitro studies using MM cell lines and primary cells to assess Wnt signaling activation and cell growth.
• In vivo studies using severe combined immunodeficient (SCID) mice and SCID-hu mouse models engrafted with MM cells.
• Administration of recombinant Wnt3a to myelomatous mice.

Main Results:

• Wnt3a activated canonical signaling in most MM cells but did not promote MM cell growth in vitro.
• In vivo, Wnt3a-expressing MM cells preserved bone mineral density and reduced tumor burden compared to control cells.
• Recombinant Wnt3a treatment in mice stimulated bone formation and attenuated MM growth.

Conclusions:

• Enhancing Wnt signaling, specifically with Wnt3a, demonstrates anabolic effects on bone.
• Wnt3a exhibits anti-MM effects in vivo by preserving bone and reducing tumor burden.
• Targeting Wnt signaling pathways holds potential for treating MM-related bone disease.